DE602004026360D1 - Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels - Google Patents

Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels

Info

Publication number
DE602004026360D1
DE602004026360D1 DE602004026360T DE602004026360T DE602004026360D1 DE 602004026360 D1 DE602004026360 D1 DE 602004026360D1 DE 602004026360 T DE602004026360 T DE 602004026360T DE 602004026360 T DE602004026360 T DE 602004026360T DE 602004026360 D1 DE602004026360 D1 DE 602004026360D1
Authority
DE
Germany
Prior art keywords
polypeptide
pharmaceutical composition
blood sugar
ligand
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004026360T
Other languages
English (en)
Inventor
Akira Hirasawa
Gozo Tsujimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHARMAFRONTIER Co Ltd
Original Assignee
PHARMAFRONTIER Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMAFRONTIER Co Ltd filed Critical PHARMAFRONTIER Co Ltd
Publication of DE602004026360D1 publication Critical patent/DE602004026360D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
DE602004026360T 2004-03-01 2004-09-03 Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels Active DE602004026360D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004056452 2004-03-01
JP2004240607 2004-08-20
PCT/JP2004/012848 WO2005083070A1 (ja) 2004-03-01 2004-09-03 血糖値の低下に供される医薬組成物

Publications (1)

Publication Number Publication Date
DE602004026360D1 true DE602004026360D1 (de) 2010-05-12

Family

ID=34914478

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026360T Active DE602004026360D1 (de) 2004-03-01 2004-09-03 Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels

Country Status (6)

Country Link
US (1) US20080004227A1 (de)
EP (1) EP1731602B1 (de)
JP (1) JP4757190B2 (de)
AT (1) ATE462723T1 (de)
DE (1) DE602004026360D1 (de)
WO (1) WO2005083070A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023408B2 (en) * 2009-03-04 2015-05-05 Meyer Nutriceuticals Llc Composition and method for control of diabetes
US8889739B2 (en) 2010-07-09 2014-11-18 President And Fellows Of Harvard College Use of trans-palmitoleate in identifying and treating metabolic disease
EP2638903A4 (de) 2010-11-09 2013-12-04 Mochida Pharm Co Ltd Suppressor zur erhöhung des blutzuckerspiegels
TW201325587A (zh) * 2011-12-22 2013-07-01 Kang Jian Biotech Corp Ltd α-葡萄糖苷酶抑制劑
GB201310664D0 (en) 2013-06-14 2013-07-31 Mars Inc Feline taste receptors
WO2021241659A1 (ja) 2020-05-29 2021-12-02 株式会社 Numt Ｆｆａｒ４を高発現させた脂肪細胞及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000000611A2 (en) * 1998-06-30 2000-01-06 Millennium Pharmaceuticals, Inc. 14273 receptor, a g-protein coupled receptor
US6448005B1 (en) * 1998-06-30 2002-09-10 Millennium Pharmaceuticals, Inc. 14723 Receptor, a novel G-protein coupled receptor
JP4707839B2 (ja) * 2000-02-07 2011-06-22 森永乳業株式会社 糖尿病予防治療剤
EP1305018A4 (de) * 2000-08-02 2006-08-30 Pharmanutrients Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung
WO2002067868A2 (en) * 2001-02-26 2002-09-06 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
EP1407767A4 (de) * 2001-06-18 2007-01-24 Yamada Sachiko Pparg-agonistische medizinische zusammensetzungen
JP4188720B2 (ja) * 2002-02-14 2008-11-26 武田薬品工業株式会社 新規スクリーニング方法
WO2003068959A1 (fr) * 2002-02-14 2003-08-21 Takeda Chemical Industries, Ltd. Nouveau procede de criblage
JPWO2004004000A1 (ja) * 2002-06-26 2005-11-04 富士通株式会社 半導体装置への電源接続構造
JP4574177B2 (ja) * 2003-01-17 2010-11-04 武田薬品工業株式会社 新規スクリーニング方法
EP1584925B1 (de) * 2003-01-17 2011-06-01 Takeda Pharmaceutical Company Limited Neues screening-verfahren

Also Published As

Publication number Publication date
US20080004227A1 (en) 2008-01-03
EP1731602A1 (de) 2006-12-13
WO2005083070A1 (ja) 2005-09-09
JP4757190B2 (ja) 2011-08-24
EP1731602B1 (de) 2010-03-31
EP1731602A4 (de) 2007-05-02
JPWO2005083070A1 (ja) 2008-01-17
ATE462723T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
WO2005084109A3 (en) Cancer specific gene mh15
Medina et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin
GB0213612D0 (en) Organic compounds
WO2010054777A3 (en) System and method for determining optimal insulin profiles
WO2007067341A3 (en) Compositions and methods for increasing insulin sensitivity
WO2006063042A3 (en) Selecting patients for therapy with a her inhibitor
ATE502646T1 (de) Fgfr agoniste
WO2005116653A3 (en) Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
DE602006015427D1 (de) Stabile glucoseoxidase-formulierungen und verfahren zur herstellung und verwendung davon
AU2013207599A1 (en) Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
ATE476422T1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
WO2005121362A3 (en) Method for selectively quantifying vegf isoforms in a biological sample and uses thereof.
DE602004026360D1 (de) Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
DK1541197T3 (da) Anvendelse af pipamperon og en SNDRI, SNRI eller SSRI til behandling af humörsvingninger eller angstlidelser
WO2006116083A3 (en) The 1, 5-anhydroglucitol (1, 5-ag) assay and a1c/1. 5-ag assay combination for measuring blood glucose excursions in general and postprandial hyperglycemia in diabetic patients
BRPI0809143B8 (pt) método in vitro para identificar um indivíduo que apresente um risco alterado para desenvolver doença cardíaca coronária (chd) ou aneurisma/dissecção
DK1824501T3 (da) Proteinhydrolysat med antidiabetisk virkning
WO2004069194A3 (en) Use of the oxidoreductase ncb50r for diagnosings and treating diabetes
Lee et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction and related risk factors
EP1860438A4 (de) Verfahren zur identifizierung des zielproteins eines wirkstoffs und verfahren zum screening eines therapeutischen wirkstoffs gegen diabetes mittels des zielproteins
WO2006010533A3 (en) Pancreatic polypeptide as target/marker of beta cell failure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1731602

Country of ref document: EP

Representative=s name: DEHMEL & BETTENHAUSEN PATENT- UND RECHTSANWAELTE,